Strategic Merger Beckons New Horizons
Pressure BioSciences, Inc. (PBIO), a company renowned for pressure-based instruments and services in the cannabis industry, unveiled a definitive agreement to acquire Uncle Bud’s, a prominent leader in natural health and wellness. The move signifies a strategic step forward for PBIO and unites Uncle Bud’s impressive product range and strong online community with PBIO’s advanced technology and scientific proficiency.
Driving Forces in Consumer Product Markets
The acquisition is poised to forge a commanding presence in various consumer product markets, harnessing PBIO’s acclaimed UltraShear technology. This platform is notably recognized for generating nanoemulsified products with unmatched bioavailability and rapid action, a pivotal attribute in the health and wellness sphere.
Celebrity Endorsement and Enthusiastic Advocacy
Grammy Award-winning artist Toni Braxton, a vocal supporter of Uncle Bud’s, expressed her elation regarding the acquisition. “I am thrilled to be a part of this exciting acquisition of Uncle Bud’s, a brand that I have loved from the beginning,” enthused Braxton. She highlighted the shared commitment to quality and innovation between the two companies and her eagerness to contribute to their growth trajectory.
Promising Projections and Expansive Innovations
Garrett Greller, director of marketing and co-founder of Uncle Bud’s, emphasized the transformative impact of the acquisition. “With a dedication to quality, effective solutions, and an impressive lineup of celebrity partners, Uncle Bud’s has democratized Hemp & CBD wellness,” Greller remarked. He also underscored the potential for innovation across various sectors such as pain relief, sexual wellness, skincare, beverages, food, and pet care.
Envisioning New Avenues for Wellness Products
Bruno Schiavi, president and co-founder of Uncle Bud’s, commented on the synergy between the two companies. “This merger with PBIO is a game-changer,” Schiavi averred, emphasizing the unique opportunities presented by the UltraShear platform in creating wellness products with superior bioavailability and clean-label attributes.
Optimism and Advancement in the Industry
From PBIO’s standpoint, Ric Schumacher, president and CEO, welcomed the expertise and experience of Uncle Bud’s team. “This dynamic combination is what we have been seeking to accelerate the penetration of the UltraShear technology across multiple markets,” Schumacher affirmed. He pointed to several new product line opportunities ripe for transformative delivery.
Financial Implications and Growth Prospects
Jeff Peterson, PBIO’s chairman, emphasized the strategic significance of the merger. “The integration of Uncle Bud’s into PBIO’s financials is expected to be immediately accretive and a major accelerator to PBIO’s top-line revenue growth,” Peterson observed. He also expressed confidence in the combined companies’ capability to attract new investment, fortify their balance sheet, and potentially uplist to major stock exchanges like NASDAQ or NYSE ahead of schedule in 2024.
Transaction Details and Impending Timeline
Under the terms of the agreement, Uncle Bud’s stockholders will receive preferred stock of PBIO, convertible into PBIO common stock with additional shares contingent on revenue and net profit targets in 2024. The Boards of Directors of both companies have unanimously approved the transaction, with closure expected by January 19, 2024, subject to customary closing conditions.
